Literature DB >> 2505199

Increased caudate dopamine turnover may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTP.

S Rose1, M Nomoto, E Kelly, G Kilpatrick, P Jenner, C D Marsden.   

Abstract

Administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to common marmosets initially impaired motor function, but a partial recovery occurred over the following weeks. At both 10 days and 4-6 weeks following MPTP treatment, [3H]dopamine ([3H]DA) uptake into synaptosomal preparations of putamen was markedly decreased. At 10 days and 4-6 weeks following MPTP treatment DA, homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in the caudate nucleus and nucleus accumbens were substantially reduced. However, the levels of HVA and DOPAC in caudate nucleus were higher at 4-6 weeks than at 10 days. The ratio of (DOPAC + HVA)/DA in caudate nucleus was elevated at 10 days following MPTP treatment and even more so at 4-6 weeks. No change in Bmax or Kd values for [3H]spiperone binding to caudate preparations were observed. The recovery of motor function in marmosets observed following MPTP treatment may result partially from a compensatory increase in caudate DA turnover by remaining neurones.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2505199     DOI: 10.1016/0304-3940(89)90550-8

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  10 in total

1.  Short and long-term changes in cerebral [14C]-2-deoxyglucose uptake in the MPTP-treated marmoset: relationship to locomotor activity.

Authors:  K K Gnanalingham; N A Milkowski; L A Smith; A J Hunter; P Jenner; C D Marsden
Journal:  J Neural Transm Gen Sect       Date:  1995

2.  The effects of central aromatic amino acid DOPA decarboxylase inhibition on the motor actions of L-DOPA and dopamine agonists in MPTP-treated primates.

Authors:  S A Treseder; M Jackson; P Jenner
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

3.  Behavioral phenotypes associated with MPTP induction of partial lesions in common marmosets (Callithrix jacchus).

Authors:  Kimberley A Phillips; Corinna N Ross; Jennifer Spross; Catherine J Cheng; Alyssa Izquierdo; K C Biju; Cang Chen; Senlin Li; Suzette D Tardif
Journal:  Behav Brain Res       Date:  2017-02-17       Impact factor: 3.332

4.  Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease--the differential effects of D1 dopamine antagonists in the primate.

Authors:  K K Gnanalingham; A J Hunter; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

5.  Serotonergic sprouting in primate MTP-induced hemiparkinsonism.

Authors:  P Gaspar; A Febvret; J Colombo
Journal:  Exp Brain Res       Date:  1993       Impact factor: 1.972

Review 6.  Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.

Authors:  Susan Duty; Peter Jenner
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

7.  Evaluation of blood-brain barrier transport and CNS drug metabolism in diseased and control brain after intravenous L-DOPA in a unilateral rat model of Parkinson's disease.

Authors:  Paulien Gm Ravenstijn; Henk-Jan Drenth; Michael J O'Neill; Meindert Danhof; Elizabeth Cm de Lange
Journal:  Fluids Barriers CNS       Date:  2012-02-08

8.  Brain structural changes in cynomolgus monkeys administered with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A longitudinal voxel-based morphometry and diffusion tensor imaging study.

Authors:  Hyeonseok S Jeong; Sang-Rae Lee; Jieun E Kim; In Kyoon Lyoo; Sujung Yoon; Eun Namgung; Kyu-Tae Chang; Bom Sahn Kim; Sejung Yang; Jooyeon J Im; Saerom Jeon; Ilhyang Kang; Jiyoung Ma; Yong-An Chung; Soo Mee Lim
Journal:  PLoS One       Date:  2018-01-10       Impact factor: 3.240

9.  Absence of alpha-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice.

Authors:  Abdelmojib Al-Wandi; Natalia Ninkina; Steven Millership; Sally J M Williamson; Paul A Jones; Vladimir L Buchman
Journal:  Neurobiol Aging       Date:  2008-12-20       Impact factor: 4.673

10.  Mirtazapine has a therapeutic potency in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice model of Parkinson's disease.

Authors:  Naoto Kadoguchi; Shinji Okabe; Yukio Yamamura; Misaki Shono; Tatsuya Fukano; Akie Tanabe; Hironori Yokoyama; Jiro Kasahara
Journal:  BMC Neurosci       Date:  2014-06-25       Impact factor: 3.288

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.